Optimizing antimicrobial dosing in the critically ill patient

Current Opinion in Critical Care

Volumn 8, Issue 5, 2002, Pages 435-440

  Goldberg, John ^a   Owens Jr , Robert C ^a,b  

^a MAINE MEDICAL CENTER   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; CARBAPENEM; CEFEPIME; CEFONICID; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN; CLARITHROMYCIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; LINCOSAMIDE; LINEZOLID; METRONIDAZOLE; MONOBACTAM DERIVATIVE; MOXIFLOXACIN; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN;

CELL PROLIFERATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; CRITICAL ILLNESS; DOSE CALCULATION; DOSE RESPONSE; ENDOCARDITIS; HUMAN; PHARMACODYNAMICS; PNEUMONIA; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS INFECTION; SYRINGE;

AGING; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; CROSS INFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTENSIVE CARE UNITS;

EID: 0036792202     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200210000-00011     Document Type: Review

References (37)

1. Ambrose PG, Owens RC Jr, Grasela D: Antimicrobial pharmacodynamics. Med Clin North Am 2000, 84:1431-1446.
2. Craig WA: Does the dose matter? Clin Infect Dis 2001, 33(suppl 3):S233-S237.
3. Calain P, Krause K-H, Vadaux P, et al.: Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis 1987, 155:187-191.
4. Chambers HF, Mills J, Drake TA, et al.: Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus. Rev Infect Dis 1984, 6(suppl 4):S870-S874.
5. Craig WA, Ebert SC: Protein binding and its significance in antibacterial therapy. Infect Dis Clin North Am 1989, 3:407-414.
6. Eagle H, Fleischman R, Levy M: Continuous vs discontinuous therapy with penicillin. N Engl J Med 1953, 238:481-486.
7. Eagle H: Effect of schedule of administration on therapeutic efficacy of penicillin: importance of aggregate time penicillin remains at effectively bactericidal levels. Am J Med 1950, 9:280-299.
8. Eagle H, Fleischman R, Mussleman AD: Effective concentrations of penicillin in vitro and in vivo for streptococci and pneumococci and Treponema. J Bacteriol 1950, 59:625-643.
9. Shah PM, Junghanns W, Stille W: Dosis-Wirkungs-Beziehung der Bakterizidie bei E. coli, K. pneumoniae und Staphylococcus aureus. Dtsch Med Wochenschr 1976, 101:325-328.
10. Ambrose PG, Owens RC Jr: New antibiotics in pulmonary and critical care medicine: focus on advanced generation quinolones and cephalosporins. Semin Respir Crit Care Med 2000, 21:19-32.
11. Dudley MN, Ambrose PG: Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Curr Opin Microbiol 2000, 3:515-521.
12. Polk R: Optimal use of modern antibiotics: emerging trends. Clin Infect Dis 1999, 29:264-274.
13. Owens RC Jr, Ambrose PG: Clinical use of the fluoroquinolones. Med Clin North Am 2000, 84:1447-1469.
14. Preston SL, Drusano GL, Berman AL, et al.: Pharmacodynamics of levofloxacin. JAMA 1998, 279:125-129.
15. Drusano GL, Johnson DE, Rosen M, et al.: Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993, 37:483-490.
16. Forrest A, Nix DE, Ballow CH, et al.: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993, 37:1073-1081.
17. Drusano GL, Preston S, Owens RC Jr, et al.: Fluoroquinolone pharmacodynamics. Clin Infect Dis 2001, 33:2091-2095.
18. Ambrose PG, Grasela DM, Grasela TH, et al.: Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001, 45:2793-2797.
19. Chen DK, McGeer A, deAzadvedo JC, et al.: Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999, 341:233-239.
20. Wortmann GW, Bennett SP: Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae. Clin Infect Dis 1999, 29: 1599-1600.
21. Davidson R, Cavalcanti R, Brunton JL, et al.: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002, 346:747-750.
22. Nicolau DP, Lacy MK, NcNabb J, et al.: Pharmacokinetics of continuous and intermittent ceftazidime in intensive care unit patients with nosocomial pneumonia. Infect Dis Clin Pract 1999, 8:45-49.
23. Ambrose PG, Owens RC Jr, Garvey MJ, et al.: Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother 2002, 49:445-453.
24. Ambrose PG, Owens RC Jr: New antibiotics in pulmonary and critical care medicine: focus on advanced generation quinolones and cephalosporins. Semin Respir Crit Care Med 2000, 21:19-32.
25. Owens RC Jr. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 2001, 21;301-319.
26. Owens RC Jr, Ambrose PG: Torsades de pointes associated with fluoroquinolones. Pharmacotherapy 2002, 22:663-672.
27. Bertino JS Jr, Owens RC Jr, Carnes T, et al.: Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis 2002, 34:861-863.
28. Lee LK, Jim MH, Tang SC, et al.: QT prolongation and torsades de pointes associated with clarithromycin. Am J Med 1998, 104:395-396.
29. Devine BJ: Gentamicin therapy. Drug Intell Clin Pharm 1974, 8:650-655.
30. Wurtz R, Itokazu G, Rodvold K: Antimicrobial dosing in obese patients. Clin Infect Dis 1997, 25:112-118.
31. Yoshikawa TT: Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis 2000, 30:931-933.
32. Livornese LL Jr, Savin D, Benz RL, et al.: Use of antibacterial agents in renal failure. Infect Dis Clin North Am 2001, 15:983-1002.
33. Tegeder I, Bremer F, Oelkers R, et al.: Pharmacokinetics of imipenemcilastatin in critically ill patients undergoing continuous venovenous hemofiltration. Antimicrob Agents Chemother 1997, 41:2640-2645.
34. Malone RS, Fish DN, Abraham EA, et al.: Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. J Antimicrob Chemother 2001, 45:2949-2954.
35. Thalhammer F, Schenk P, Burgmann H, et al.: Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother 1998, 42:2417-2420.
36. Matzke GR, Frye RF, Joy MS, et al.: Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrob Agents Chemother 2000, 44:1639-1644.
37. Malone RS, Fish DN, Abraham EA, et al.: Pharmacokinetics of cefepime during continuous renal replacement therapy in critically-ill patients. J Antimicrob Chemother 2001, 45:3148-3155.